Today: 21 May 2026
XRP price slides 6% as U.S. crypto bill vote and Fed pause keep traders cautious
29 January 2026
2 mins read

XRP price slides 6% as U.S. crypto bill vote and Fed pause keep traders cautious

New York, January 29, 2026, 13:53 ET — Trading hours

  • XRP has dropped roughly 6% over the last 24 hours, following a wider crypto market downturn
  • A U.S. Senate panel has pushed forward a crypto market-structure bill, though its passage remains far from assured
  • Ripple is promoting a new treasury platform, buoyed by an appeals court ruling in its favor in a protracted investor lawsuit

XRP dropped 6.1% in the last 24 hours, slipping to $1.80 on Thursday amid a broader crypto sell-off triggered by new U.S. policy updates. According to CoinMarketCap data, XRP’s 24-hour trading volume hit roughly $4.2 billion.

The timing is crucial for XRP as Washington reenters the picture. Clearer federal guidelines could open doors for institutions to trade and hold tokens more freely, but this is happening just as the Federal Reserve hints it’s holding off on further rate cuts.

The global crypto market cap dropped to roughly $2.86 trillion, sliding 5.65% in the past 24 hours, according to CoinMarketCap. Bitcoin took a 6.57% hit, trading at $83,876, while ether declined 6.78% to $2,802.

On Wednesday, the Fed left its benchmark rate steady at 3.50%-3.75%. Chair Jerome Powell described the economy as “solid” and noted it had “surprised us with its strength.” Michael Pearce, chief U.S. economist at Oxford Economics, predicted an “extended pause.” Reuters

On Thursday in Washington, the Senate Agriculture Committee pushed forward a bill giving the Commodity Futures Trading Commission control over spot crypto markets—meaning the actual trading of tokens—and laying out rules for digital-asset exchanges, brokers, and dealers. But the measure still needs backing from Democrats to pass the Senate. Senator Cory Booker said lawmakers are “almost in the red zone” as he demanded more rules related to decentralized finance. Reuters reported the White House plans to meet banking and crypto leaders Monday to chart a way ahead. Reuters

Ripple, known for its ties to XRP, is steering the conversation back to products. It rolled out “Ripple Treasury, Powered by GTreasury,” targeting corporate finance teams handling cash and digital assets. The platform promises to optimize liquidity in real time while cutting settlement delays and FX risk in cross-border payments. “The integration of GTreasury’s 40 years of treasury expertise with Ripple’s cutting-edge blockchain infrastructure creates something that has never existed before,” the company said in its announcement. When acquiring GTreasury, Ripple CEO Brad Garlinghouse noted that treasury teams could “finally put their trapped capital to work.” PYMNTS.com

The legal pressure continues. In an unpublished memo filed Jan. 27, the U.S. Court of Appeals for the Ninth Circuit upheld summary judgment against investors claiming XRP sales were an unregistered securities offering. The court ruled the Securities Act claims were barred by a three-year statute of repose—a strict deadline starting from the first public offer. The panel noted Ripple was offering XRP publicly as early as 2013.

That case runs parallel to Ripple’s previous clash with the SEC. Back in August 2025, the SEC dropped its lawsuit against Ripple but kept a $125 million fine and a ban on selling XRP to institutional buyers in place, after both parties agreed to drop their appeals, Reuters reported.

The risk is clear-cut: the Senate bill could get stuck, and a sharper pullback in risk assets might drown out company-specific news. XRP often behaves like a high-beta play on overall sentiment, not merely on Ripple developments.

Traders are turning their attention to Monday’s White House discussions and Ripple’s XRP Community Day, a virtual event planned for Feb. 11-12. Ripple executives will address issues like ETFs (exchange-traded funds) and “wrapped” XRP—tokenized forms meant to operate across different blockchains. ripple.com

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Ford stock price today: F shares edge up as lawmaker probes CATL battery plans ahead of earnings
Previous Story

Ford stock price today: F shares edge up as lawmaker probes CATL battery plans ahead of earnings

Applied Digital (APLD) stock slides nearly 7% after insider sale filing — what investors watch next
Next Story

Applied Digital (APLD) stock slides nearly 7% after insider sale filing — what investors watch next

Go toTop